Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

How might Medicare price negotiations impact Novo Nordisk's battle in the marketplace with Eli Lilly? Lilly's type 2 diabetes drug Mounjaro and obesity drug Zepbound aren't eligible for Medicare ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. The ...

A group of lawmakers are urging President Donald Trump to reject pharmaceutical companies’ efforts to pause the Biden administration’s drug-price cuts.

The founder, managing principal, and chief investment officer of AQR Capital Management, […] Eli Lilly and Company ( NYSE:LLY ) will increase its dividend from last year's comparable payment on the ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Eli Lilly (LLY) closed at $753.98 in the latest trading session, marking a +1.57% move from the prior day. Today's Research Daily features new research reports on 16 major stocks, including Eli ...

The board of Eli Lilly and Company ( NYSE:LLY ) has announced that it will be paying its dividend of $1.50 on the 10th... Here's why they chose Amgen (NASDAQ: AMGN), Eli Lilly (NYSE: LLY), and Summit ...